查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球预防性疫苗市场
市场调查报告书
商品编码
1176602

2023-2030 年全球预防性疫苗市场

Global Preventive Vaccine Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期内 (2023-2030)，预防疫苗的市场规模预计将以 5.3% 的复合年增长率增长。

预防性疫苗是一种生物製品，可刺激针对特定病原体的免疫力。 疫苗通常含有类似于引起疾病的生物体的物质，通常由生物体或毒素的死亡或减毒版本製成。

市场动态

推动全球预防性疫苗市场发展的主要因素是世界上疾病数量的增加、研发支出的增加以及公众对预防性疫苗的认识。 新产品发布的增加促进了预防性疫苗市场的增长。

增加研发投资和增加新产品发布预计将推动市场增长。

越来越多地采用这些预防和治疗麻疹、白喉、脊髓灰质炎、风疹和流感等多种疾病的预防性疫苗产品，促进了预防性疫苗市场的增长。它是推动力。 此外，世界上越来越多的疾病也在推动市场的增长。 许多医疗保健公司正在加紧研发活动以开发新产品。

预防性疫苗用于预防或预防疾病在儿童和成人中的传播。 由于各种疾病的增加，这些疫苗的市场正在全球范围内扩大。 此外，主要参与者对新型疫苗和技术先进产品的研究和开发不断增加，预计也将在市场增长中发挥重要作用。

各种新产品的发布、监管批准和研究正在推动市场增长。 例如，2022 年 4 月 11 日，田边三菱製药公司宣布 BIKEN（大阪大学微生物病研究组）联合开发了白喉、百日咳预防、破伤风、b 型流感嗜血桿菌（Hib）和急性骨髓炎（已宣布它已向厚生劳动省申请脊髓灰质炎联合疫苗的上市许可）。 根据国家免疫规划，针对这五种疾病的联合疫苗被选为2014年指定的高优先级疫苗。

预计预防性疫苗的副作用会阻碍市场的增长。

然而，与不同类型疫苗相关的各种轻微副作用可能会阻碍市场增长。 接种 DTaP 疫苗后可能会出现发烧、注射部位肿胀和疼痛、烦躁、疲劳、呕吐和食慾不振。 接种流感疫苗后，注射部位可能会出现红肿、肌肉疼痛、头痛和发烧等症状。

流感疫苗接种后可能会出现鼻塞、流鼻涕、头痛和气喘。 MMR 疫苗接种后可能会出现脸颊和颈部肿胀、关节僵硬和暂时性疼痛（主要发生在成人和少女身上）。 接种轮状病毒疫苗后，可能会出现烦躁、呕吐和暂时性轻度腹泻。

COVID-19 影响分析

疫情对全球金融预期、运营和危机应对策略产生了积极影响。 COVID-19 的爆发严重影响了医疗保健行业。 由于 COVID 疫苗的各种研究和临床试验已经认真开始，预防性疫苗市场因 COVID 而获得了巨大收益。 迫切需要一种疫苗来防止 COVID 及其变体在全球传播。 世界各地正在发生各种举措、产品发布、创新、合作和合併，推动了市场的增长。 例如，2022 年 11 月 10 日，赛诺菲和葛兰素史克宣布，他们共同开发的下一代 COVID-19 加强疫苗 VidPrevtyn Beta 获得欧盟委员会批准，用于 18 岁及以上成年人的 COVID-19 预防。宣布。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 增加研发投资
      • 新产品发布激增
      • 疾病发病率增加
    • 约束因素
      • 疫苗的不良反应
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按疫苗类型分类

  • 减毒疫苗
  • 灭活□□疫苗
  • 亚基、重组、缀合物、多醣疫苗
  • mRNA疫苗
  • 类毒素疫苗
  • 病毒载体疫苗

第8章给药途径

  • 口语
  • 皮下给药
  • 其他

第9章疾病适应症

  • 肺炎球菌疾病
  • 水痘
  • 人乳头瘤病毒
  • 流感
  • 脑膜炎球菌感染
  • MMR（麻疹、腮腺炎、风疹）
  • 小儿麻痹症
  • 肝炎
  • 登革热
  • DPT（白喉、百日咳、破伤风）
  • 轮状病毒
  • 黄热病
  • 伤寒
  • 其他

第 10 章最终用户

  • 成人
  • 儿科

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第13章公司简介

  • 阿斯利康
    • 公司概况
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Astellas Pharma, Inc.
  • Pfizer, Inc
  • Johnson & Johnson
  • GSK plc
  • Merck & Co., Inc.
  • Sanofi
  • Bavarian Nordic
  • Emergent Biosolutions
  • Mitsubishi Tanabe Pharma Corporation

第14章 DataM

简介目录
Product Code: DMBT43

Market Overview

Preventive Vaccine Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 5.3% during the forecast period (2023-2030).

A preventive vaccine is a kind of biological preparation which stimulates immunity to a specific pathogen. A vaccine commonly contains an agent similar to the disease-causing microbe and is usually made from killed or weakened forms of the microorganism or its toxins.

Market Dynamics

The major factors driving the global preventive vaccine market are an increase in the number of diseases globally, rising research and development expenditure and awareness among the population regarding these preventive vaccines. An increase in novel product launches contributes to the growth of the preventive vaccine market.

The increasing investment in R&D and rising novel product launches are expected to drive the market's growth.

The rising adoption of these preventive vaccine products for the prevention or treatment of various diseases, such as measles, diphtheria, polio, rubella, influenza and many more and the rising number of novel product launches drive the preventive vaccine market. An increase in diseases globally is also aiding the market growth. There has been an increase in R&D activities by many healthcare companies to develop novel products.

The preventive vaccine is used for the prevention of diseases and the spreading of these diseases in children and adults. The market for these vaccines is increasing worldwide due to the increasing number of different diseases. Moreover, the increase in research and development of novel vaccines and the availability of technologically advanced products by key players are also expected to play a vital role in the market's growth.

Various novel product launches, regulatory approvals and research studies contribute to the market's growth. For instance, in April 11, 2022, Mitsubishi Tanabe Pharma Corporation announced that BIKEN (The Research Foundation for Microbial Diseases of Osaka University) submitted the application to the Ministry of Health, Labour and Welfare for their jointly developed combination vaccine marketing authorization for diphtheria, prophylaxis of pertussis, tetanus, Haemophilus influenzae type b (Hib) and acute poliomyelitis (polio). According to the "National Immunization Plan," this combination vaccine utilized for five diseases has been chosen as the vaccine with high development priority specified in 2014.

The side effects associated with preventive vaccines are expected to hamper the market's growth.

However, various minor side effects associated with different types of vaccines may hinder the market's growth. Fever, swelling or soreness where the shot was given, fussiness, tiredness, vomiting and loss of appetite can occur after DTaP vaccination. Redness or swelling happens where the shot is given, and muscle aches, headaches and fever can happen after influenza vaccination.

After influenza vaccination, nasal congestion, runny nose, headache and wheezing can happen. In the cheeks or neck, swelling of the glands or stiffness and temporary pain in the joints (mostly in adults or teenage women) sometimes happen after MMR vaccination. Irritability, vomiting, or temporary, mild diarrhea, can occur after the rotavirus vaccine.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The preventive vaccine market has experienced huge profits due to COVID, as various research and clinical trials got started in full swing for COVID vaccine. An urgent need for vaccines to prevent the spreading of COVID and its variant across the globe. Various initiatives, product launches, innovations, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in November 10, 2022, Sanofi and GSK announced the approval of their jointly developed VidPrevtyn Beta, the next-generation COVID-19 booster vaccine, by the European Commission for COVID-19 prevention in adults aged 18 years and older.

Segment Analysis

The live-attenuated vaccines segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The live-attenuated vaccines segment is the highest market holder in the global preventive vaccine market. The global preventive vaccine market is segmented based on vaccine type: live-attenuated vaccines, inactivated vaccines, subunit, recombinant, conjugate, and polysaccharide vaccines, mRNA vaccines, toxoid vaccines and viral vector vaccines. The live-attenuated vaccines segment is the largest market shareholder due to its better efficacy and results, increasing diseases and rising adoption of these preventive vaccines.

The live-attenuated vaccines utilize an attenuated or weakened form of the microbe that causes a disease. As these vaccines are like the natural infection they help avert, they provide a long-lasting and strong immune response. Most of the live vaccines, in just 1 or 2 doses, can provide a lifetime of protection contrary to the microbe and the disease caused by it. These vaccines are used for the protection against smallpox, rotavirus, yellow fever, chickenpox and combined vaccine of measles, mumps, and rubella (MMR).

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in February 24, 2022, Mitsubishi Tanabe Pharma Corporation announced that GlaxoSmithKline plc and Medicago Inc., its affiliated company, jointly announced receiving full approval for COVIFENZ (COVID-19 vaccine) from Health Canada. COVIFENZ is a virus-like particle vaccine that is administered with the pandemic adjuvant of GSK indicated for COVID-19 prevention.

Geographical Analysis

North America holds the largest market share in the global preventive vaccine market.

North America dominates the global preventive vaccine market, primarily due to its large population, excellent medical infrastructure, and rising number of diseases. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of types of vaccines for prevention of different disease indications such as pneumococcal disease, varicella, human papillomavirus, influenza, meningococcal disease, MMR (measles, mumps, rubella), polio, hepatitis, dengue, DPT (diphtheria, pertussis, and tetanus), rotavirus, yellow fever, typhoid fever and more, increase in pharmaceutical establishment across the region and government approvals and the presence of key players in the region are contributing to the growth of the preventive vaccine market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. For instance, in October 10, 2022, GSK plc announced approval for its BOOSTRIX (Reduced Diphtheria Toxoid, Tetanus Toxoid and Acellular Pertussis Vaccine) by the US Food and Drug Administration (FDA) for immunization during the pregnancy to prevent pertussis (whooping cough) in infants.

Competitive Landscape

The preventive vaccine market is moderately competitive with local and global companies' presence. AstraZeneca, Astellas Pharma Inc., Pfizer, Inc, Johnson & Johnson, GSK plc, Merck & Co., Inc., Sanofi, Bavarian Nordic, Emergent Biosolutions, Mitsubishi Tanabe Pharma Corporation and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in August 16, 2022, GSK plc announced its completion of the acquisition of Affinivax Inc, a Cambridge-based clinical-stage biopharmaceutical company. Affinivax has initiated a novel class of vaccine development. The most advanced of them are next-generation pneumococcal vaccines.

GSK PLC.

Overview: GlaxoSmith Kline is a company that develops and provides vaccines, medicines and several consumer healthcare-related products. Its products impact the health of humans on a large scale.

Product Portfolio:

VidPrevtyn Beta: It is the next-generation COVID-19 booster vaccine developed for COVID-19 prevention in adults aged 18 years and older and approved by the European Commission.

Key Developments: In February 3, 2021, GlaxoSmithKline plc and CureVac N.V. announced a novel collaboration of €150M for the joint development of next-generation mRNA vaccines for preventing COVID-19 virus with the capability for a multi-valent approach to deal with multiple emerging variants with one vaccine.

The global preventive vaccine market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in investment in research and development
      • 4.1.1.2. Surge in novel product launches
      • 4.1.1.3. Increasing incidence of diseases
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with vaccines
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Vaccine Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 7.1.2. Market Attractiveness Index, By Vaccine Type
  • 7.2. Live-attenuated vaccines*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Inactivated vaccines
  • 7.4. Subunit, recombinant, conjugate, and polysaccharide vaccines
  • 7.5. mRNA vaccines
  • 7.6. Toxoid vaccines
  • 7.7. Viral vector vaccines

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Subcutaneous
  • 8.4. Other

9. By Disease Indication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 9.1.2. Market Attractiveness Index, By Disease Indication
  • 9.2. Pneumococcal Disease *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Varicella
  • 9.4. Human Papilloma Virus
  • 9.5. Influenza
  • 9.6. Meningococcal Disease
  • 9.7. MMR (Measles, Mumps, Rubella)
  • 9.8. Polio
  • 9.9. Hepatitis
  • 9.10. Dengue
  • 9.11. DPT (diphtheria, pertussis, and tetanus)
  • 9.12. Rotavirus
  • 9.13. Yellow Fever
  • 9.14. Typhoid Fever
  • 9.15. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Adults *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Pediatrics

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. AstraZeneca *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Astellas Pharma, Inc.
  • 13.3. Pfizer, Inc
  • 13.4. Johnson & Johnson
  • 13.5. GSK plc
  • 13.6. Merck & Co., Inc.
  • 13.7. Sanofi
  • 13.8. Bavarian Nordic
  • 13.9. Emergent Biosolutions
  • 13.10. Mitsubishi Tanabe Pharma Corporation

LIST NOT EXHAUSTIVE

14. Global Preventive Vaccine Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and End-User
  • 14.3. Contact Us